Evidence map›Paper›PMID 34074337›Full record

ArticleImplementation science communications2021

Feasibility of a pharmacy-led intervention to de-implement non-guideline-concordant proton pump inhibitor use.

Jackson S Musuuza, Emily Fong, Paul Lata, Katie Willenborg, Mary Jo Knobloch, Margaret J Hoernke, Andrew R Spiel, Jessica S Tischendorf, Katie J Suda, Nasia Safdar

Open access · goldAbstract read
In one paragraph

Article in Implementation science communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Jackson S MusuuzaWilliam S. Middleton Memorial Veterans Hospital, Madison, WI, USA. musuuza@wisc.edu.ORCID http://orcid.org/0000-0001-9447-7659
Emily FongWilliam S. Middleton Memorial Veterans Hospital, Madison, WI, USA.
Paul LataWilliam S. Middleton Memorial Veterans Hospital, Madison, WI, USA.
Katie WillenborgWilliam S. Middleton Memorial Veterans Hospital, Madison, WI, USA.
Mary Jo KnoblochWilliam S. Middleton Memorial Veterans Hospital, Madison, WI, USA.
Margaret J HoernkeWilliam S. Middleton Memorial Veterans Hospital, Madison, WI, USA.
Andrew R SpielDivision of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
Jessica S TischendorfWilliam S. Middleton Memorial Veterans Hospital, Madison, WI, USA.
Katie J SudaVA Pittsburgh Healthcare System, Pittsburgh, PA, USA.
Nasia SafdarWilliam S. Middleton Memorial Veterans Hospital, Madison, WI, USA.
University of Wisconsin–Madison · USWilliam S. Middleton Memorial Veterans Hospital · USUniversity of Pittsburgh · US

Funding

University of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9M
Improving patient safety by promoting guideline-concordant Proton Pump Inhibitor UseI21HX002618 · VA · WM S. MIDDLETON MEMORIAL VETERANS HOSP · PI MUSUUZA, JACKSON SSENTALO · 2019 to 2020
–
Health Services Research and Development 1 I21 HX002618-01HSRD VA I21 HX002618NCATS NIH HHS UL1 TR002373
6 · The paper itself

Abstract

backgroundProton pump inhibitors (PPIs) are among the most prescribed medications and are often used unnecessarily. PPIs are used for the treatment of heartburn and acid-related disorders. Emerging evidence indicates that PPIs are associated with serious adverse events, such as increased risk of Clostridioides difficile infection. In this study, we designed and piloted a PPI de-implementation intervention among hospitalized non-intensive care unit patients.

methodsUsing the Systems Engineering Initiative for Patient Safety (SEIPS) model as the framework, we developed an intervention with input from providers and patients. On a bi-weekly basis, a trainee pharmacist reviewed a random sample of eligible patients' charts to assess if PPI prescriptions were guideline-concordant; a recommendation to de-implement non-guideline-concordant PPI therapy was sent when applicable. We used convergent parallel mixed-methods design to evaluate the feasibility and outcomes of the intervention.

resultsDuring the study period (September 2019 to August 2020), 2171 patients with an active PPI prescription were admitted. We randomly selected 155 patient charts for review. The mean age of patients was 70.9 ± 9 years, 97.4% were male, and 35% were on PPIs for ≥5 years. The average time (minutes) needed to complete the intervention was as follows: 5 to assess if the PPI was guideline-concordant, 5 to provide patient education, and 7 to follow-up with patients post-discharge. After intervention initiation, the week-to-week mean number of PPI prescriptions decreased by 0.5 (S<0.0001). Barriers and facilitators spanned the 5 elements of the SEIPS model and included factors such as providers' perception that PPIs are low priority medications and patients' willingness to make changes to their PPI therapy if needed, respectively. Ready access to pharmacists was another frequently reported facilitator to guideline-concordant PPI. Providers recommended a PPI de-implementation intervention that is specific and tells them exactly what they need to do with a PPI treatment.

conclusionIn a busy inpatient setting, we developed a feasible way to assess PPI therapy, de-implement non-guideline-concordant PPI use, and provide follow-up to assess any unintended consequences. We documented barriers, facilitators, and provider recommendations that should be considered before implementing such an intervention on a large scale.

Identifiers

PMID34074337
PMCPMC8171048
OpenAlexW3163950942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.